Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.

Trudeau, Maureen; Eisenhauer, Elizabeth; Higgins, Brian; Letendre, Francois; Lofters, W.; Norris, B.; Vandenberg, Theodore A.; Delorme, F.; Muldal, A.

doi:10.1200/jco.1996.14.2.422

Cited by 143 publications

(43 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose-limiting toxicity for this combination is myelosuppression, specifically a high incidence of grade 4 neutropenia and febrile neutropenia, which is manageable with haematopoietic growth factors (Morales et al, 2004). A clear dose -response relationship has been demonstrated for epirubicin and docetaxel as single agents, with or without G-CSF support (Bastholt et al, 1996;Trudeau et al, 1996;Sparano et al, 2000;Milla-Santos et al, 2001). However, it was recently reported that dose-escalated epirubicin and docetaxel every 3 weeks, with prophylactic G-CSF, resulted in severe myelosuppression without improving efficacy, compared with other studies of taxane/ anthracycline combinations (Fabi et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

et al. 2007

View full text Add to dashboard Cite

This study was designed to evaluate the efficacy and tolerability of a weekly schedule of epirubicin in combination with docetaxel in the first-line treatment of patients with metastatic breast cancer (MBC). A total of 43 women with MBC not previously treated with chemotherapy for metastatic disease received weekly epirubicin 25 mg m À2 and docetaxel 25 mg m À2 for a maximum of five cycles (total cumulative epirubicin dose of p900 mg m À2 ). Dose reduction was not permitted. Objective response and evaluation of toxicity profile were the primary study end points; time to progression and overall survival were secondary end points. Patients were followed for a median of 21 (4 -38) months. Analysis was by intent to treat; 33 patients completed five cycles of therapy, and the median dose of epirubicin administered to the 43 patients was 23 mg m À2 . Twenty-five patients (58%) achieved a partial response and one (2%) achieved a complete response. An additional 12 patients (28%) had stable disease. The median time to progression was 11 months (95% confidence intervals (CI) 7 -14) overall, and 13 months (95% CI 12 -14) in the 26 patients who responded to treatment. Median overall survival was 25 months for responders and 14 months for nonresponders. Grade 3/4 neutropenia occurred in 16% of patients and in 6% of cycles. One patient developed cardiac toxicity (20% reduction in left ventricular ejection fraction). The combination of epirubicin plus docetaxel is highly active in MBC, with a manageable toxicity profile. Such a weekly schedule might provide a valuable treatment option for MBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Routine premedication with glucocorticoids can diminish the incidence of hypersensitivity during paclitaxel or docetaxel therapy from 30% to 3% 20,48 . With premedication, the incidence of hypersensitivity reactions to paclitaxel is between 1% and 3% regardless of infusion time (1, 3, or 24 hours).…”

Section: Skin Testingmentioning

confidence: 99%

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

et al. 2014

View full text Add to dashboard Cite

“…Docetaxel, a novel mitotic spindle poison that acts as a microtubule stabilizer, has only infrequently been associated with the development of pulmonary toxicity, that is usually of the type of hypersensitivity pneumonitis not meeting the criteria for NCPE [61,62]. Notably, a fluid retention syndrome is known to occur in as many as 20%-60% of nonpremedicated patients treated with the agent, but this is typically peripheral, with pleural effusions reported only occasionally [63][64][65]. Although no NCPE has been attributed to docetaxel as a single agent to date, several cases have been reported with its combination with gemcitabine and radiotherapy [8,66,67].…”

Section: Cytotoxic Drugsmentioning

confidence: 99%

Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy

Briasoulis

Pavlidis

2001

The Oncologist

View full text Add to dashboard Cite

Noncardiogenic pulmonary edema (NCPE) is a rare and less well-recognizable pulmonotoxic syndrome of anticancer therapy than pneumonitis/fibrosis. NCPE is a clinical syndrome characterized by simultaneous presence of severe hypoxemia, bilateral alveolar infiltrates on chest radiograph, and no evidence of left atrial hypertension/congestive heart failure. The diagnosis of drug-related NCPE relies upon documented exclusion of any infectious, metabolic, or cancer-related causes. The Oncologist 2001;6:153-161 www.TheOncologist.com Correspondence: Evangelos Briasoulis, M.D., Medical Oncology Department, Ioannina University, Ioannina, 45110, Greece. Telephone and Fax: 30-651-99394; e-mail: ebriasou@otenet.gr. Received August 15, 2000; accepted for publication November 30, 2000. ©AlphaMed Press 1083-7159/2001 INTRODUCTIONSeveral cancer therapeutic drugs are known to induce pulmonary damage, which may result in a variety of clinicopathologic syndromes with minor to severe clinical consequences [1]. Clinical syndromes associated with drug-induced pulmonary toxicity include pneumonitis/fibrosis, hypersensitivity lung disease, and noncardiogenic pulmonary edema (NCPE)/acute respiratory distress syndrome (ARDS). These syndromes share a similar symptomatology but differ in regard to the time-relation to cancer treatment, the radiographic findings, the duration of pulmonary damage, and the long-term outcome [2]. Non-specific symptomatology of cough, progressive dyspnea, and often a low-grade fever alert clinicians confronted with the diagnostic challenge to recognize subclinical syndromes and differentiate fully developed drug-induced pulmonary reactions from lung injuries caused by infectious, cardiac, and neoplastic causes.

show abstract

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.

Cited by 143 publications

References 11 publications

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer

Management of Hypersensitivity to Platinum- and Taxane-Based Chemotherapy: cepo Review and Clinical Recommendations

Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy

Contact Info

Product

Resources

About